RankAlpha logo
Back to Rankings

KLRS

Kalaris TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
View Chart
Current thesis
Primary company disclosures still support a funded path through key milestones, with screening underway in the Phase 1b/2 study, manufacturing batch work completed, and preliminary TH103 data expected in 1H 2027 [#SEC-8K-2026-05-12].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +17.7.
What can break
Execution risk remains meaningful because value creation depends on advancing a Phase 1b/2 retina study toward a planned Phase 3 start by year-end 2027 [#SEC-8K-2026-05-12][#SEC-8K-2026-03-17].
Momentum
74
Value
59
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.00 · Bull $9.00 · Bear $1.50
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-26 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $18.71
Why
Momentum74 · Δ7d -
Value59 · Δ7d +17.7
Sentiment48 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
74
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
39% active weight
Current posture
7d trendImproving
Δ7d
+17.7
Δ21d
-0.7
Sentiment
48
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 74.5 / Value 58.9 / Sentiment 48.0

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$95.61M
Beta
-0.10
Shares Out
23.79M
P/E (TTM) · Derived
-1.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.69
Rev YoY
-100.0%
EPS YoY
-81.8%
Gross Margin
-
Op Margin
-
Net Debt
-$116.53M
Current Ratio
12.14
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology